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Dear Editor,
With great interest we read the paper of
Fraisse et al. [1] in which the authors
document the intravenous (i.v.) use of
sildenafil in paediatric patients with
congenital heart disease and pulmonary
hypertension. The findings of the
authors are important, since the com-
mercially available sildenafil solution
for injection (Revatio 0.8 mg/ml,
50 ml) is only licensed for administra-
tion as a bolus injection and unwanted
excessive hypotensive effects may
occur after administration of a bolus
dose. Recently, we administered silde-
nafil intravenously to two paediatric
patients at the Erasmus MC Sophia
Children’s Hospital. One of the children
(girl, age 4.5 years, 17 kg) was treated
with sildenafil orally for 16 days (3 mg/
kg daily) and subsequently with silde-
nafil i.v. bolus injections for 27 days
(0.5–1.0 mg/kg three times daily).
Bolus sildenafil injections resulted in
reductions in arterial systolic and dia-
stolic pressures of approximately 20%.
The second child (boy, neonate, age
23 days, 3.0 kg) received one bolus
sildenafil i.v. dose of 0.2 mg/kg, after
which arterial systolic and diastolic
pressures dropped also by approxi-
mately 20%. Thereafter, a sildenafil
continuous infusion was started with a
loading dose of 0.4 mg/kg in 3 h and
maintenance dose of 1.9 mg/kg daily
for 5 days in total. During the continu-
ous i.v. infusion, no marked fluctuations
in arterial systolic and diastolic pres-
sures were observed.
As described by Fraisse et al. [1],
maintenance infusions of sildenafil
may have clear advantages. However,
in order to correctly administer con-
tinuous i.v. (maintenance) infusions of
sildenafil to paediatric patients, the
commercially available product may
frequently require dilution prior to
administration. The current authorized
version of the summary of product
characteristics of Revatio, and major
handbooks such as those by Trissel [2]
and Bing [3], as well as other pharma-
ceutical literature sources, do not
provide information on how sildenafil
dilutions for continuous i.v. adminis-
tration should be prepared and stored.
Also Fraisse et al. [1] did not explicitly
state how the maintenance infusion
should be prepared and stored.
To address this issue, we studied the
stability of two Revatio dilutions
(0.067 and 0.667 mg/ml) in dextrose
5%, which is the diluent of choice in
most neonatal and paediatric intensive
care units. Both dilutions were stored in
50-ml Luer-LokTM polypropylene
syringes (BD Plastipak, Spain) at
ambient room temperature (20–25C)
and at 37C (laboratory incubator) for
24 h and 7 days. Thereafter, and after
performing a system suitability test and
the preparation of two three-point
aqueous calibration curves (concentra-
tion ranges are 0.04–0.08 and
0.4–0.8 mg/ml), we determined the
concentration of sildenafil in both dilu-
tions using a validated HPLC method
(C18 ODS-3 5-lm column, 50:50 v/v
acetonitrile/ammonium acetate 10 mM
mobile phase, detection at 292 nm;
Shimadzu LC20 diode array detector
and HPLC system), and the coefficients
of variation for repeatability, reproduc-
ibility and accuracy were found to be
0.1, 1.7 and 1.8%, respectively. The
system suitability test complied with the
general requirements of the United
States Pharmacopeia [tailing and
capacity (k0) factors were about 0.97
and 3.3, respectively]. The calibration
curves exhibited satisfactory correla-
tion coefficient and goodness-of-fit
values (both C0.999).
Measurement of the sildenafil
concentrations in both dilutions at the
end of the incubation periods (1 and
7 days) suggested no marked degra-
dation at either temperature (room
temperature or 37C), since all of the
concentrations measured were higher
than 95.4% (percent of nominal con-
centration at t = 0 h) and since the
peak-purity index was 1.000 in all of
the measurements, indicating the
absence of degradation products.
Our findings therefore suggest that
Revatio dilutions in dextrose 5% in
the range 0.067–0.667 mg/ml are
chemically stable for up to 1 week at
room temperature (and hence clini-
cally usable provided that antiseptic
conditions are strictly applied during
compounding). Our findings thus
provide the pharmaceutical basis to
enable administration of diluted sil-
denafil as a maintenance infusion to
paediatric patients.
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